Approved leukemia drug monitored in real patients

NCT ID NCT04826523

Summary

This study monitored the safety and effectiveness of the approved leukemia drug venetoclax in real-world patients with acute myeloid leukemia (AML) in South Korea. About 150 adult patients who were prescribed the drug for the first time were observed for about 7 months during their regular treatment. Researchers tracked side effects and how well the drug worked to control the cancer in a routine medical setting.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chonnam National University Hwasun Hospital /ID# 257478

    Hwasun-gun, Jeonranamdo, 58128, South Korea

  • Gachon University Gil Medical Center /ID# 239008

    Incheon, Gyeonggido, 21565, South Korea

  • Korea University Anam Hospital /ID# 231022

    Seoul, Seoul Teugbyeolsi, 02841, South Korea

  • Kosin University Gospel Hospital /ID# 257399

    Busan, Busan Gwang Yeogsi, 49267, South Korea

  • Kyungpook National University Hospital /ID# 257398

    Daegu, Daegu Gwang Yeogsi, 41944, South Korea

  • Pusan National University Hospital /ID# 239010

    Busan, Busan Gwang Yeogsi, 49241, South Korea

  • Samsung Medical Center /ID# 239009

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Hospital /ID# 257477

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Yeungnam University Medical Center /ID# 239007

    Daegu, 42415, South Korea

  • Yonsei University Health System Severance Hospital /ID# 239006

    Seoul, 03722, South Korea

Conditions

Explore the condition pages connected to this study.